首页 > 最新文献

Nephrologe最新文献

英文 中文
[COVID-19]. [新冠肺炎]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-01-21 DOI: 10.1007/s11560-020-00477-9
Christiane Erley, Werner Kleophas, Jürgen Floege
{"title":"[COVID-19].","authors":"Christiane Erley, Werner Kleophas, Jürgen Floege","doi":"10.1007/s11560-020-00477-9","DOIUrl":"https://doi.org/10.1007/s11560-020-00477-9","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-020-00477-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38860099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Transplantation]. (移植)。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-05-11 DOI: 10.1007/s11560-021-00496-0
C Morath, B Tönshoff
{"title":"[Transplantation].","authors":"C Morath, B Tönshoff","doi":"10.1007/s11560-021-00496-0","DOIUrl":"https://doi.org/10.1007/s11560-021-00496-0","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 3","pages":"127-128"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-021-00496-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38988132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects]. [有效治疗与anca相关的血管粥样硬化并减少副作用的策略]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-08-30 DOI: 10.1007/s11560-021-00527-w
Ulf Schönermarck, Volker Vielhauer

The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remission of severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), glucocorticoids are used as well as cyclophosphamide and rituximab. The current recommendations enable a more rapid tapering of steroid dose and advise caution in the use of plasmapheresis. Rituximab and azathioprine are available options for maintenance of remission. The choice of medication and duration of remission maintenance are oriented particularly to the risk of recurrence. The importance of low-dose steroids has not yet been finally clarified. New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a minimized steroid treatment in the future. The treatment of eosinophilic granulomatosis with polyangiitis (EGPA) is less evidence-based and consists of glucocorticoids, immunosuppressive agents depending on the severity and increasingly more biologics, e.g. interleukin‑5 blockade. Supportive measures (e.g. vaccinations, infection prophylaxis, cardiovascular risk management) are increasing in importance. Future treatment strategies must take the individual risk (e.g. ANCA subtype, relapse risk) more into consideration for selection and duration of treatment.

抗中性粒细胞胞浆抗体(ANCA)相关血管增生的发病机制是复杂的;然而,近年来更好的理解使新的治疗方法成为可能。近年来,将治疗相关的毒性降到最低是优先考虑的问题。对于伴有多血管炎(GPA)和显微镜下多血管炎(MPA)的严重肉芽肿病的诱导缓解,糖皮质激素以及环磷酰胺和利妥昔单抗被使用。目前的建议是更迅速地减少类固醇剂量,并建议谨慎使用血浆置换。利妥昔单抗和硫唑嘌呤是维持缓解的可用选择。药物的选择和缓解维持的持续时间主要取决于复发的风险。低剂量类固醇的重要性尚未得到最终澄清。新的治疗方法,如C5a受体抑制剂avacopan,可以使未来的类固醇治疗最小化。嗜酸性肉芽肿病合并多血管炎(EGPA)的治疗缺乏循证证据,包括糖皮质激素、根据严重程度使用免疫抑制剂和越来越多的生物制剂,如白细胞介素- 5阻断剂。支持性措施(如接种疫苗、感染预防、心血管风险管理)的重要性日益增加。未来的治疗策略必须更多地考虑个体风险(如ANCA亚型、复发风险)来选择和治疗时间。
{"title":"[Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects].","authors":"Ulf Schönermarck,&nbsp;Volker Vielhauer","doi":"10.1007/s11560-021-00527-w","DOIUrl":"https://doi.org/10.1007/s11560-021-00527-w","url":null,"abstract":"<p><p>The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remission of severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), glucocorticoids are used as well as cyclophosphamide and rituximab. The current recommendations enable a more rapid tapering of steroid dose and advise caution in the use of plasmapheresis. Rituximab and azathioprine are available options for maintenance of remission. The choice of medication and duration of remission maintenance are oriented particularly to the risk of recurrence. The importance of low-dose steroids has not yet been finally clarified. New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a minimized steroid treatment in the future. The treatment of eosinophilic granulomatosis with polyangiitis (EGPA) is less evidence-based and consists of glucocorticoids, immunosuppressive agents depending on the severity and increasingly more biologics, e.g. interleukin‑5 blockade. Supportive measures (e.g. vaccinations, infection prophylaxis, cardiovascular risk management) are increasing in importance. Future treatment strategies must take the individual risk (e.g. ANCA subtype, relapse risk) more into consideration for selection and duration of treatment.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 6","pages":"360-371"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39403531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Long-term clinical outcomes of acute kidney failure]. [急性肾衰竭的长期临床结果]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2020-12-22 DOI: 10.1007/s11560-020-00476-w
Alexander Weidemann, Achim Jörres
{"title":"[Long-term clinical outcomes of acute kidney failure].","authors":"Alexander Weidemann,&nbsp;Achim Jörres","doi":"10.1007/s11560-020-00476-w","DOIUrl":"https://doi.org/10.1007/s11560-020-00476-w","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 1","pages":"40-42"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-020-00476-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39086869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Renal replacement procedures in the very old]. [在非常古老的肾脏替代手术中]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-08-13 DOI: 10.1007/s11560-021-00518-x
Ulrike Bechtel, Mariam Abu-Tair

Very old people have a 1‑year mortality on hemodialysis, which in association with comorbidities and a catheter as dialysis access exceeds 30%; however, meta-analyses show that timely preparation and individually selected procedures decisively improve the morbidity and mortality even in old age. With increasing age and frailty the treatment targets shift away from prolongation of the lifespan to improvement of the quality of life. In this way the preference of home dialysis procedures, also as assisted peritoneal dialysis, can also achieve importance just as specialist nephrological treatment without renal replacement therapy with a palliative treatment target. In advanced age comorbidities, cognitive impairment, frailty and the overall prognosis determine the meaningful approach. Even with the placement of a vascular access there are other criteria for making decisions in very old people with respect to the anastomosis site and timing of access placement. Recommendations on the duration and frequency of dialysis follow the quality of life with incremental and at the end of life also with decremental treatment regimens. The demographic development is a special challenge for nephrology with an increase in older patients. Timely clarification of all renal replacement procedures and establishment of individual treatment targets with a careful selection of the dialysis modality and intensity can make a decisive contribution to improvement of the prognosis and particularly to the quality of life even in the very old.

非常老的人在血液透析中有1年的死亡率,与合并症和透析导管相关的死亡率超过30%;然而,荟萃分析显示,及时准备和个别选择的程序决定性地提高发病率和死亡率,即使在老年人。随着年龄的增长和身体的衰弱,治疗目标从延长寿命转向改善生活质量。通过这种方式,家庭透析程序的偏好,也作为辅助腹膜透析,也可以达到重要的专科肾病治疗没有肾脏替代治疗与姑息治疗的目标。在老年合并症,认知障碍,虚弱和整体预后决定了有意义的方法。即使是血管通道的放置也有其他的标准来决定老年人的吻合位置和通道放置的时间。关于透析持续时间和频率的建议遵循生活质量,并在生命结束时采用减量治疗方案。随着老年患者的增加,人口发展对肾脏病学来说是一个特殊的挑战。及时澄清所有肾脏替代手术,并建立个人治疗目标,仔细选择透析方式和强度,可以对改善预后,特别是对老年人的生活质量做出决定性贡献。
{"title":"[Renal replacement procedures in the very old].","authors":"Ulrike Bechtel,&nbsp;Mariam Abu-Tair","doi":"10.1007/s11560-021-00518-x","DOIUrl":"https://doi.org/10.1007/s11560-021-00518-x","url":null,"abstract":"<p><p>Very old people have a 1‑year mortality on hemodialysis, which in association with comorbidities and a catheter as dialysis access exceeds 30%; however, meta-analyses show that timely preparation and individually selected procedures decisively improve the morbidity and mortality even in old age. With increasing age and frailty the treatment targets shift away from prolongation of the lifespan to improvement of the quality of life. In this way the preference of home dialysis procedures, also as assisted peritoneal dialysis, can also achieve importance just as specialist nephrological treatment without renal replacement therapy with a palliative treatment target. In advanced age comorbidities, cognitive impairment, frailty and the overall prognosis determine the meaningful approach. Even with the placement of a vascular access there are other criteria for making decisions in very old people with respect to the anastomosis site and timing of access placement. Recommendations on the duration and frequency of dialysis follow the quality of life with incremental and at the end of life also with decremental treatment regimens. The demographic development is a special challenge for nephrology with an increase in older patients. Timely clarification of all renal replacement procedures and establishment of individual treatment targets with a careful selection of the dialysis modality and intensity can make a decisive contribution to improvement of the prognosis and particularly to the quality of life even in the very old.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 5","pages":"261-268"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-021-00518-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39320857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Consensus Paper "Palliative renal care"]. [共识文件“姑息性肾脏护理”]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-09-24 DOI: 10.1007/s11560-021-00536-9
Christoph Gerhard, Wolfgang Pommer

Aspects of palliative medicine such as withholding and withdrawal of dialysis, initiating conservative therapy and cooperative end-of-life care have increasingly become part of standard renal care. The corresponding transfer of knowledge of palliative medicine principles has so far been lacking in training and further education. This consensus paper proposes structured curricular training for the kidney team based on principles of palliative care.

暂停和停止透析、开始保守治疗和合作临终关怀等姑息医学方面已日益成为标准肾脏护理的一部分。迄今为止,在培训和继续教育方面缺乏相应的姑息医学原则知识转移。这篇共识论文提出了基于姑息治疗原则的肾脏团队的结构化课程培训。
{"title":"[Consensus Paper \"Palliative renal care\"].","authors":"Christoph Gerhard,&nbsp;Wolfgang Pommer","doi":"10.1007/s11560-021-00536-9","DOIUrl":"https://doi.org/10.1007/s11560-021-00536-9","url":null,"abstract":"<p><p>Aspects of palliative medicine such as withholding and withdrawal of dialysis, initiating conservative therapy and cooperative end-of-life care have increasingly become part of standard renal care. The corresponding transfer of knowledge of palliative medicine principles has so far been lacking in training and further education. This consensus paper proposes structured curricular training for the kidney team based on principles of palliative care.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 6","pages":"380-385"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39481931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Update on: Experiences from the German COVID-19 register]. [更新:来自德国COVID-19登记的经验]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-08-19 DOI: 10.1007/s11560-021-00528-9
Elion Hoxha
{"title":"[Update on: Experiences from the German COVID-19 register].","authors":"Elion Hoxha","doi":"10.1007/s11560-021-00528-9","DOIUrl":"https://doi.org/10.1007/s11560-021-00528-9","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 5","pages":"311-313"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-021-00528-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39338227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Acute kidney injury]. [急性肾损伤]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-02-18 DOI: 10.1007/s11560-021-00489-z
Thorsten Feldkamp, Oliver Witzke
{"title":"[Acute kidney injury].","authors":"Thorsten Feldkamp,&nbsp;Oliver Witzke","doi":"10.1007/s11560-021-00489-z","DOIUrl":"https://doi.org/10.1007/s11560-021-00489-z","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 2","pages":"65"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-021-00489-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25395799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[SARS-CoV-2/COVID-19-epidemiology and prevention]. [SARS-CoV-2/COVID-19-流行病学和预防]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2020-12-15 DOI: 10.1007/s11560-020-00472-0
Bernd Salzberger, Felix Buder, Benedikt Lampl, Boris Ehrenstein, Florian Hitzenbichler, Thomas Holzmann, Barbara Schmidt, Frank Hanses

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R0) is between 2 and 3 and the median incubation period is 6 days (range 2-14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5-10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4-1.8% and excess mortality could not be observed.

自 2019 年 12 月以来,严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)在全球迅速传播。截至 2020 年 6 月底,许多地区都出现了第一波疫情。本文回顾了目前有关流行病学和预防的知识。SARS-CoV-2 主要在上下呼吸道复制,尤其通过飞沫和气溶胶传播。基本繁殖数(R0)估计在 2 到 3 之间,中位潜伏期为 6 天(范围为 2 到 14 天)。与相关的 SARS-CoV 和中东呼吸综合征(MERS-CoV)一样,超级传播事件在传播中发挥了重要作用。大部分感染并无并发症,但有 5-10%的感染者会出现中度或重度病程。肺炎、心脏受累和血栓栓塞是导致住院治疗的最常见表现。病程复杂的风险因素包括高龄、高血压、糖尿病、慢性心血管疾病和肺部疾病以及免疫缺陷。目前,各年龄组的感染致死率(IFR)估计在 0.5% 至 1%之间。许多地区采取了各种措施减少社会接触,从而限制了疫情的爆发。据估计,德国第一波疫情的发病率为 0.4%-1.8%,无法观察到过高的死亡率。
{"title":"[SARS-CoV-2/COVID-19-epidemiology and prevention].","authors":"Bernd Salzberger, Felix Buder, Benedikt Lampl, Boris Ehrenstein, Florian Hitzenbichler, Thomas Holzmann, Barbara Schmidt, Frank Hanses","doi":"10.1007/s11560-020-00472-0","DOIUrl":"10.1007/s11560-020-00472-0","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R<sub>0</sub>) is between 2 and 3 and the median incubation period is 6 days (range 2-14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5-10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4-1.8% and excess mortality could not be observed.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 1","pages":"3-9"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38731591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Update on: SARS-CoV-2/COVID-19-epidemiology and prevention]. [最新情况:SARS-CoV-2/COVID-19-流行病学和预防]。
Q4 Medicine Pub Date : 2021-01-01 Epub Date: 2021-08-19 DOI: 10.1007/s11560-021-00529-8
Bernd Salzberger, Felix Buder, Benedikt Lampl, Boris Ehrenstein, Florian Hitzenbichler, Stilla Bauernfeind, Thomas Holzmann, Barbara Schmidt, Frank Hanses
{"title":"[Update on: SARS-CoV-2/COVID-19-epidemiology and prevention].","authors":"Bernd Salzberger, Felix Buder, Benedikt Lampl, Boris Ehrenstein, Florian Hitzenbichler, Stilla Bauernfeind, Thomas Holzmann, Barbara Schmidt, Frank Hanses","doi":"10.1007/s11560-021-00529-8","DOIUrl":"10.1007/s11560-021-00529-8","url":null,"abstract":"","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 5","pages":"307-310"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39338228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephrologe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1